SCHEMBL4427310

SCHEMBL4427310

CNC(=O)Cn1c(=O)oc2ccccc21

nearest known ligand 0.71

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.71
HPGD P15428 2/20 0.66
KMT2A Q03164 4/20 0.64
POLB P06746 3/20 0.64
MEN1 O00255 2/20 0.64
CYP1A2 P05177 3/20 0.63
CYP2C19 P33261 3/20 0.63
CYP2D6 P10635 2/20 0.63
CYP3A4 P08684 2/20 0.63
PKM P14618 1/20 0.63
TP53 P04637 1/20 0.63
CDYL2 Q8N8U2 2/20 0.61
CDYL Q9Y232 2/20 0.61
CDY1; CDY1B Q9Y6F8 2/20 0.61
CYP2C9 P11712 1/20 0.61
CBX7 O95931 1/20 0.61
L3MBTL1 Q9Y468 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8570374 0.85 MAPK1 (0.71) HPGDKMT2APOLBMEN1CYP1A2
SCHEMBL29004242 0.85 LMNA (0.71) LMNAHPGDKMT2APOLBMEN1
SCHEMBL4426178 0.84 NPC1 (0.67) LMNAHPGDKMT2APOLBMEN1
SCHEMBL4419286 0.84 LMNA (0.66) LMNAHPGDKMT2APOLBMEN1
SCHEMBL4415935 0.83 LMNA (1.00) LMNAHPGDKMT2APOLBMEN1
SCHEMBL13995838 0.83 HPGD (0.71) LMNAHPGDKMT2APOLBMEN1
SCHEMBL14667527 0.82 LMNA (0.63) LMNAHPGDKMT2APOLBMEN1
SCHEMBL6717405 0.82 HPGD (0.66) LMNAHPGDKMT2APOLBMEN1
SCHEMBL4416281 0.81 LMNA (0.65) LMNAHPGDKMT2APOLBMEN1
SCHEMBL2947194 0.81 HPGD (0.73) LMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293775-B2 Benzoxazolone derivatives, processes for preparing them and their uses UCB PHARMA, S.A. (BE) 2012-10-23 US disclosed
EP-1756071-B1 BENZOXAZOLONE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB PHARMA SA (BE) 2009-08-26 EP disclosed
US-20070299118-A1 Benzoxazolone Derivatives, Processes For Preparing Them And Their Uses UCB, S.A. (BE) 2007-12-27 US disclosed
EP-1756071-A1 BENZOXAZOLONE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB, S.A. (BE) 2007-02-28 EP disclosed
WO-2005118561-A1 BENZOXAZOLONE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB, S.A. (BE) 2005-12-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070299118-A1 Benzoxazolone Derivatives, Processes For Preparing Them And Their Uses PARK7, SNCA, GABRA5 LMNA 1221/4885HPGD 232/4885KMT2A 2566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.